Since BRD4 bromodomains were previously shown to bind to acetylated Lys-310 of p65 in HEK293T cells (43) and BET bromodomain inhibitors disrupt the p65-BRD4 interaction in cancer cells (43, 44), we used nanoluciferase bioluminescence resonance energy transfer (NanoBRET) to quantify the interactions of p65 and BRD4 in INS 832/13 cells. Here, BRD4 is linked to cancer.